Are you over 18 and want to see adult content?
More Annotations
![A complete backup of https://makhmalbaf.com](https://www.archivebay.com/archive6/images/be35b946-ac1e-40a2-840e-6c5fa4f08b71.png)
A complete backup of https://makhmalbaf.com
Are you over 18 and want to see adult content?
![A complete backup of https://topratedcatfoods.com](https://www.archivebay.com/archive6/images/78588e8c-63ab-4e2a-b65c-f9064f79b29a.png)
A complete backup of https://topratedcatfoods.com
Are you over 18 and want to see adult content?
![A complete backup of https://iowadnr.gov](https://www.archivebay.com/archive6/images/24e0d153-7e3f-4c37-a7aa-546b980d2392.png)
A complete backup of https://iowadnr.gov
Are you over 18 and want to see adult content?
![A complete backup of https://decipherzone.com](https://www.archivebay.com/archive6/images/8b93c4e2-75d8-4390-be26-dcd64ad1d177.png)
A complete backup of https://decipherzone.com
Are you over 18 and want to see adult content?
![A complete backup of https://washburn.edu](https://www.archivebay.com/archive6/images/23750932-2e7d-4c52-8bde-f8be64edf37f.png)
A complete backup of https://washburn.edu
Are you over 18 and want to see adult content?
![A complete backup of https://livetoto79.com](https://www.archivebay.com/archive6/images/efbc4d24-fee6-4796-a119-d25c19103029.png)
A complete backup of https://livetoto79.com
Are you over 18 and want to see adult content?
![A complete backup of https://elmark.com.pl](https://www.archivebay.com/archive6/images/f791e69f-d5a6-4131-a7a6-19fd1dd7813d.png)
A complete backup of https://elmark.com.pl
Are you over 18 and want to see adult content?
![A complete backup of https://palanga-airport.lt](https://www.archivebay.com/archive6/images/d407e228-777a-4f96-9f88-203496b83b26.png)
A complete backup of https://palanga-airport.lt
Are you over 18 and want to see adult content?
![A complete backup of https://energizeinc.com](https://www.archivebay.com/archive6/images/7fa0e4ef-bb9c-4340-99b4-7643b4c31ffa.png)
A complete backup of https://energizeinc.com
Are you over 18 and want to see adult content?
![A complete backup of https://homeimprovementall.com](https://www.archivebay.com/archive6/images/42616525-d2b2-42da-9296-3db5f18e7e63.png)
A complete backup of https://homeimprovementall.com
Are you over 18 and want to see adult content?
![A complete backup of https://ripost.hu](https://www.archivebay.com/archive6/images/8d0ae329-49e1-4ff9-ad9e-e69a1dd003f9.png)
A complete backup of https://ripost.hu
Are you over 18 and want to see adult content?
![A complete backup of https://batimes.com.ar](https://www.archivebay.com/archive6/images/897468bf-f735-4218-a9ca-0acd5285a00d.png)
A complete backup of https://batimes.com.ar
Are you over 18 and want to see adult content?
Favourite Annotations
![A complete backup of hardwareheaven.com](https://www.archivebay.com/archive/17f49aed-e278-4bb7-a758-23fda03efa7c.png)
A complete backup of hardwareheaven.com
Are you over 18 and want to see adult content?
![A complete backup of paraoaltoeavante.com.br](https://www.archivebay.com/archive/ac46223b-a87f-491b-b53a-6ce1d4639c85.png)
A complete backup of paraoaltoeavante.com.br
Are you over 18 and want to see adult content?
![A complete backup of bunnyhomes.blogspot.com](https://www.archivebay.com/archive/cf6f0bb0-96a8-41b2-86da-36b5dd748ce6.png)
A complete backup of bunnyhomes.blogspot.com
Are you over 18 and want to see adult content?
![A complete backup of dbdermatologiabarcelona.com](https://www.archivebay.com/archive/b98d242b-02cf-463c-b8f7-eb0a7f91c360.png)
A complete backup of dbdermatologiabarcelona.com
Are you over 18 and want to see adult content?
![A complete backup of nedirnedemek.com](https://www.archivebay.com/archive/5db581ab-96cd-4564-914c-1dea2351ef97.png)
A complete backup of nedirnedemek.com
Are you over 18 and want to see adult content?
Text
TEAM – ATOMWISE
Atomwise uses artificial intelligence for drug discovery. We design new molecules for the hardest targets. Our discoveries help our partners deliver better medicines faster. COMPANY – ATOMWISE Our portfolio of joint ventures and partnerships with leading pharmaceutical, agrochemical, and emerging biotechnology companies represents a collective deal value approaching $7 billion. To date, Atomwise has raised over $174 million from leading venture capital firms to advance our mission to make better medicines, faster.IN THE NEWS
In The News Atomwise wins “Best use of AI in Health and Medicine” in 5th Annual AI Awards. Date. March 8, 2021. Source. The Global Achievement Awards for AI; Awards.Ai. Tags. AI. AI Biotech. AI drugdiscovery.
ATOMWISE RAISES $123 MILLION IN SERIES B FINANCING CO-LED Atomwise Raises $123 Million in Series B Financing Co-Led by B Capital Group and Sanabil. New financing will enable Atomwise to further scale the largest artificial intelligence (AI)-driven drug discovery portfolio in history and expand $5 billion+ deal pipeline for small molecule drug discovery. SAN FRANCISCO — August 11, 2020 —Atomwise
POSITIONS – ATOMWISE Atomwise uses artificial intelligence for drug discovery. We design new molecules for the hardest targets. Our discoveries help our partners deliver better medicines faster. ATOMWISE ANNOUNCES MULTI-YEAR, MULTI-TARGET AGREEMENT WITH Atomwise Inc. today announced a multi-year agreement with Eli Lilly and Company to apply Atomwise’s patented artificial intelligence (AI) technology in support of Lilly’s preclinical drug discovery efforts. The companies will collaborate on up to ten drug targets selected by Lilly, with the goal of HOW ATOMNET® TECHNOLOGY IMPROVES DRUG DESIGN USING AtomNet® technology is the first drug discovery algorithm to use a deep convolutional neural network. This type of network came to prominence only a few years ago and has a unique property: it excels at understanding complex concepts as a combination of smaller and smaller pieces of information. This property is a key reason whyconvolutional
RAPID ID OF FUNCTIONAL INHIBITORS OF HUMAN POLRMT BY DEEP A virtual library of 7.2 million commercially available compounds was screened against POLRMT using AtomNet® model - an artificial intelligence platform that applies deep convolutional neural networks to drug discovery. The top 72 hit compounds were acquired and tested in OCI-AML2 human acute myeloid leukemia cells for a potentialdecrease of
ATOMWISE FINDS FIRST EVIDENCE TOWARDS NEW EBOLA TREATMENTS Atomwise finds first evidence towards new Ebola treatments. Date. March 24, 2015. Four months ago, Atomwise launched a virtual search for safe, existing medicines that could be repurposed to treat the Ebola virus. This week, the first evidence has been found that two drugs predicted by Atomwise’s artificial intelligence technology may ATOMWISE – BETTER MEDICINES FASTER.PARTNERSTEAMNEWSBLOGCONTACTCAREERS Atomwise uses artificial intelligence for drug discovery. We design new molecules for the hardest targets. Our discoveries help our partners deliver better medicines faster.TEAM – ATOMWISE
Atomwise uses artificial intelligence for drug discovery. We design new molecules for the hardest targets. Our discoveries help our partners deliver better medicines faster. COMPANY – ATOMWISE Our portfolio of joint ventures and partnerships with leading pharmaceutical, agrochemical, and emerging biotechnology companies represents a collective deal value approaching $7 billion. To date, Atomwise has raised over $174 million from leading venture capital firms to advance our mission to make better medicines, faster.IN THE NEWS
In The News Atomwise wins “Best use of AI in Health and Medicine” in 5th Annual AI Awards. Date. March 8, 2021. Source. The Global Achievement Awards for AI; Awards.Ai. Tags. AI. AI Biotech. AI drugdiscovery.
ATOMWISE RAISES $123 MILLION IN SERIES B FINANCING CO-LED Atomwise Raises $123 Million in Series B Financing Co-Led by B Capital Group and Sanabil. New financing will enable Atomwise to further scale the largest artificial intelligence (AI)-driven drug discovery portfolio in history and expand $5 billion+ deal pipeline for small molecule drug discovery. SAN FRANCISCO — August 11, 2020 —Atomwise
POSITIONS – ATOMWISE Atomwise uses artificial intelligence for drug discovery. We design new molecules for the hardest targets. Our discoveries help our partners deliver better medicines faster. ATOMWISE ANNOUNCES MULTI-YEAR, MULTI-TARGET AGREEMENT WITH Atomwise Inc. today announced a multi-year agreement with Eli Lilly and Company to apply Atomwise’s patented artificial intelligence (AI) technology in support of Lilly’s preclinical drug discovery efforts. The companies will collaborate on up to ten drug targets selected by Lilly, with the goal of HOW ATOMNET® TECHNOLOGY IMPROVES DRUG DESIGN USING AtomNet® technology is the first drug discovery algorithm to use a deep convolutional neural network. This type of network came to prominence only a few years ago and has a unique property: it excels at understanding complex concepts as a combination of smaller and smaller pieces of information. This property is a key reason whyconvolutional
RAPID ID OF FUNCTIONAL INHIBITORS OF HUMAN POLRMT BY DEEP A virtual library of 7.2 million commercially available compounds was screened against POLRMT using AtomNet® model - an artificial intelligence platform that applies deep convolutional neural networks to drug discovery. The top 72 hit compounds were acquired and tested in OCI-AML2 human acute myeloid leukemia cells for a potentialdecrease of
ATOMWISE FINDS FIRST EVIDENCE TOWARDS NEW EBOLA TREATMENTS Atomwise finds first evidence towards new Ebola treatments. Date. March 24, 2015. Four months ago, Atomwise launched a virtual search for safe, existing medicines that could be repurposed to treat the Ebola virus. This week, the first evidence has been found that two drugs predicted by Atomwise’s artificial intelligence technology may PORTFOLIO – ATOMWISE The Atomwise-Velocity Pharmaceutical Development joint venture has initiated five development programs in areas of high medical need including cancer, autoimmune diseases, and clotting disorders. The Atomwise-Atropos joint venture aims to use the AtomNet® technology and the Atropos senescence platform to develop novel drugs for aging PIPELINE – ATOMWISE Our Pipeline. Each disease area and drug program in our pipeline takes us one step closer to transforming preclinical R&D using computational chemistry to discover small molecule drugs more efficiently than traditional approaches to deliver better medicines, faster. R&D Pipeline. Co-Developed.IN THE NEWS
AI Biotech. AI drug discovery. BioPharma. Featured Atomwise wins “Best use of AI in Health and Medicine” in 5th Annual AI Awards. Date. March 8, 2021. Source. The Global Achievement Awards for AI;Awards.Ai. Tags.
OUR JOURNEY
The AtomwiseStory. While at the University of Toronto, we saw early on how machine learning and convolutional neural networks could be applied for image recognition. We founded Atomwise to prove the concept that the same technology could be applied to drug discovery by performing computational screens to find molecules worth testing inthe lab.
PUBLICATIONS
Publication SPOP and OTUD7A Control EWS–FLI1 Protein Stability to Govern Ewing Sarcoma Growth Siyuan Su, Jianfeng Chen, Yao Jiang, Ying Wang, Tamara Vital, Jiaming Zhang, Christian Laggner, Kong T. Nguyen, Zhichuan Zhu, Alex W. Prevatte, BIOPHARMA PARTNERSHIPS Atomwise unlocks the potential of challenging targets and opens up access to billions of compounds to help our partners discover novel, potent and selective compounds. Our team of world-class medicinal chemists closely collaborates with our partners at every step of the drug discovery process from hit identification to lead optimization,and
ATOMWISE BLOG
April 02, 2021. Events, ACS2021. At the American Chemical Society Spring 2021 Virtual Meeting & Expo, several Atomwise members and partners were selected to present their research and work. Learn what our Atoms have been working on below and ATOMNET® TECHNOLOGY HAS THE POWER TO IMPACT EARLY DRUG AtomNet® technology is the first drug discovery algorithm to use a deep convolutional neural network – the same AI technology that recognizes faces in a crowd enables self-driving cars, and allows you to talk to your phone. It uses a statistical approach that extracts the insights from millions of experimental affinity measurements and MACHINE LEARNING SCALES VIRTUAL SCREENS TO >10B COMPOUND The availability and accessibility of chemistry-on-demand and ultra-large screening libraries (ULSLs) give rise to an opportunity for mining new chemical spaces for novel scaffolds. This combination of cheap à la carte synthesis that covers tens of billions of molecules may mark the inception of a golden age of computationalapproaches, where
EFFICIENT GPU IMPLEMENTATION OF AUTODOCK VINA A key step in virtual high throughput screenings (VHTS) of small molecules for structure based drug discovery is the docking procedure that aims to find most likely binding modes of trial ligands to target proteins. One of the foremost tools for this procedure today is AutoDock Vina and its efficient parallel implementation, Smina. ATOMWISE – BETTER MEDICINES FASTER.PARTNERSTEAMNEWSBLOGCONTACTCAREERS Atomwise uses artificial intelligence for drug discovery. We design new molecules for the hardest targets. Our discoveries help our partners deliver better medicines faster. COMPANY – ATOMWISE Our portfolio of joint ventures and partnerships with leading pharmaceutical, agrochemical, and emerging biotechnology companies represents a collective deal value approaching $7 billion. To date, Atomwise has raised over $174 million from leading venture capital firms to advance our mission to make better medicines, faster.TEAM – ATOMWISE
Atomwise uses artificial intelligence for drug discovery. We design new molecules for the hardest targets. Our discoveries help our partners deliver better medicines faster.IN THE NEWS
In The News Atomwise wins “Best use of AI in Health and Medicine” in 5th Annual AI Awards. Date. March 8, 2021. Source. The Global Achievement Awards for AI; Awards.Ai. Tags. AI. AI Biotech. AI drugdiscovery.
ATOMWISE RAISES $123 MILLION IN SERIES B FINANCING CO-LED Atomwise Raises $123 Million in Series B Financing Co-Led by B Capital Group and Sanabil. New financing will enable Atomwise to further scale the largest artificial intelligence (AI)-driven drug discovery portfolio in history and expand $5 billion+ deal pipeline for small molecule drug discovery. SAN FRANCISCO — August 11, 2020 —Atomwise
CAREERS AT ATOMWISE
Atomwise can only make better medicines faster with the collective efforts and expertise of our teammates, or Atoms. Individually, Atoms have a localized impact thanks to their work on the bleeding edge where AI meets drug discovery. Collectively, we are making a broad impact on the future of human health by solving some of the hardestproblems
CONTACT US – ATOMWISE Please complete our contact form and a member of our team will get in touch as soon as possible. Atomwise is committed to protecting and respecting your privacy, and we’ll only use your personal information to administer your account and to provide the products and services you requested from us. From time to time, we would like tocontact
BIOPHARMA PARTNERSHIPS Atomwise unlocks the potential of challenging targets and opens up access to billions of compounds to help our partners discover novel, potent and selective compounds. Our team of world-class medicinal chemists closely collaborates with our partners at every step of the drug discovery process from hit identification to lead optimization,and
ATOMWISE ANNOUNCES MULTI-YEAR, MULTI-TARGET AGREEMENT WITHELI AND LILLY COMPANYELI LILLY PRODUCTSELI LILLY STOCK Atomwise Inc. today announced a multi-year agreement with Eli Lilly and Company to apply Atomwise’s patented artificial intelligence (AI) technology in support of Lilly’s preclinical drug discovery efforts. The companies will collaborate on up to ten drug targets selected by Lilly, with the goal of ATOMWISE & AIMS COLLABORATORS AT ACS FALL 2020 VIRTUAL AIMS Program Collaborations. Through the AIMS Awards Program, Atomwise supports promising researchers with AI resources for small-molecule drug discovery that help advance their work. This year, a number of our research collaborations were selected to present at ATOMWISE – BETTER MEDICINES FASTER.PARTNERSTEAMNEWSBLOGCONTACTCAREERS Atomwise uses artificial intelligence for drug discovery. We design new molecules for the hardest targets. Our discoveries help our partners deliver better medicines faster. COMPANY – ATOMWISE Our portfolio of joint ventures and partnerships with leading pharmaceutical, agrochemical, and emerging biotechnology companies represents a collective deal value approaching $7 billion. To date, Atomwise has raised over $174 million from leading venture capital firms to advance our mission to make better medicines, faster.TEAM – ATOMWISE
Atomwise uses artificial intelligence for drug discovery. We design new molecules for the hardest targets. Our discoveries help our partners deliver better medicines faster.IN THE NEWS
In The News Atomwise wins “Best use of AI in Health and Medicine” in 5th Annual AI Awards. Date. March 8, 2021. Source. The Global Achievement Awards for AI; Awards.Ai. Tags. AI. AI Biotech. AI drugdiscovery.
ATOMWISE RAISES $123 MILLION IN SERIES B FINANCING CO-LED Atomwise Raises $123 Million in Series B Financing Co-Led by B Capital Group and Sanabil. New financing will enable Atomwise to further scale the largest artificial intelligence (AI)-driven drug discovery portfolio in history and expand $5 billion+ deal pipeline for small molecule drug discovery. SAN FRANCISCO — August 11, 2020 —Atomwise
CAREERS AT ATOMWISE
Atomwise can only make better medicines faster with the collective efforts and expertise of our teammates, or Atoms. Individually, Atoms have a localized impact thanks to their work on the bleeding edge where AI meets drug discovery. Collectively, we are making a broad impact on the future of human health by solving some of the hardestproblems
CONTACT US – ATOMWISE Please complete our contact form and a member of our team will get in touch as soon as possible. Atomwise is committed to protecting and respecting your privacy, and we’ll only use your personal information to administer your account and to provide the products and services you requested from us. From time to time, we would like tocontact
BIOPHARMA PARTNERSHIPS Atomwise unlocks the potential of challenging targets and opens up access to billions of compounds to help our partners discover novel, potent and selective compounds. Our team of world-class medicinal chemists closely collaborates with our partners at every step of the drug discovery process from hit identification to lead optimization,and
ATOMWISE ANNOUNCES MULTI-YEAR, MULTI-TARGET AGREEMENT WITHELI AND LILLY COMPANYELI LILLY PRODUCTSELI LILLY STOCK Atomwise Inc. today announced a multi-year agreement with Eli Lilly and Company to apply Atomwise’s patented artificial intelligence (AI) technology in support of Lilly’s preclinical drug discovery efforts. The companies will collaborate on up to ten drug targets selected by Lilly, with the goal of ATOMWISE & AIMS COLLABORATORS AT ACS FALL 2020 VIRTUAL AIMS Program Collaborations. Through the AIMS Awards Program, Atomwise supports promising researchers with AI resources for small-molecule drug discovery that help advance their work. This year, a number of our research collaborations were selected to present at PORTFOLIO – ATOMWISE The Atomwise-Velocity Pharmaceutical Development joint venture has initiated five development programs in areas of high medical need including cancer, autoimmune diseases, and clotting disorders. The Atomwise-Atropos joint venture aims to use the AtomNet® technology and the Atropos senescence platform to develop novel drugs for agingOUR JOURNEY
The AtomwiseStory. While at the University of Toronto, we saw early on how machine learning and convolutional neural networks could be applied for image recognition. We founded Atomwise to prove the concept that the same technology could be applied to drug discovery by performing computational screens to find molecules worth testing inthe lab.
PIPELINE – ATOMWISE Our Pipeline. Each disease area and drug program in our pipeline takes us one step closer to transforming preclinical R&D using computational chemistry to discover small molecule drugs more efficiently than traditional approaches to deliver better medicines, faster. R&D Pipeline. Co-Developed. POSITIONS – ATOMWISE Atomwise uses artificial intelligence for drug discovery. We design new molecules for the hardest targets. Our discoveries help our partners deliver better medicines faster.PUBLICATIONS
Publication SPOP and OTUD7A Control EWS–FLI1 Protein Stability to Govern Ewing Sarcoma Growth Siyuan Su, Jianfeng Chen, Yao Jiang, Ying Wang, Tamara Vital, Jiaming Zhang, Christian Laggner, Kong T. Nguyen, Zhichuan Zhu, Alex W. Prevatte,AIMS AWARDS PROGRAM
The AIMS Awards program, started in 2017, is designed to support promising researchers with resources that will help advance their work. AIMS Awards target research focused on finding solutions for complex human and nonhuman health conditions. ATOMWISE ANNOUNCES MULTI-YEAR, MULTI-TARGET AGREEMENT WITH Atomwise Inc. today announced a multi-year agreement with Eli Lilly and Company to apply Atomwise’s patented artificial intelligence (AI) technology in support of Lilly’s preclinical drug discovery efforts. The companies will collaborate on up to ten drug targets selected by Lilly, with the goal of HOW ATOMNET® TECHNOLOGY IMPROVES DRUG DESIGN USING AtomNet® technology is the first drug discovery algorithm to use a deep convolutional neural network. This type of network came to prominence only a few years ago and has a unique property: it excels at understanding complex concepts as a combination of smaller and smaller pieces of information. This property is a key reason whyconvolutional
RAPID ID OF FUNCTIONAL INHIBITORS OF HUMAN POLRMT BY DEEP A virtual library of 7.2 million commercially available compounds was screened against POLRMT using AtomNet® model - an artificial intelligence platform that applies deep convolutional neural networks to drug discovery. The top 72 hit compounds were acquired and tested in OCI-AML2 human acute myeloid leukemia cells for a potentialdecrease of
NEGLECTED DISEASE PROGRAM REIMAGINES DRUG DISCOVERY WITH About AIMS. The AIMS Award program, started in 2017, is designed to support promising researchers with resources that will help advance their work.AIMS Awards target research focused on finding solutions for complex human and nonhuman health conditions. To date, Atomwise has funded 7 rounds of AIMS Awards, completing over 100 collaborative projects and accepting over 775 projects This website stores cookies on your computer. These cookies are used to improve your website experience and provide more personalized services to you, both on this website and through other media. To find out more about the cookies we use, see our Privacy Policy. We won't track your information when you visit our site. But in order to comply with your preferences, we'll have to use just one tiny cookie so that you're not asked to make this choice again.Accept Decline
* Partners
* Corporate & Academic Partnerships* AIMS Awards
* CADDS
* Team
* News
* Contact
* Careers
* Partners
* Corporate & Academic Partnerships* AIMS Awards
* CADDS
* Team
* News
* Contact
* Careers
ARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY We design new molecules for the hardest targets. Our discoveries help our partners deliver BETTER MEDICINES FASTER.Our Technology
Careers
__ Previous
__ Next
ENABLING SUCCESS
Our machine learning has improved hit rates by up to 10,000x and we’re able to deliver accuracy comparable to wet lab experiments. We screen for potency, selectivity, and polypharmacology, and guard against off-target toxicity.UNPARALLELED SPEED
Atomwise delivers results 100 times faster than ultra high throughput screening. Our deep convolutional neural network, AtomNet, screens more than 100 million compounds each day. TACKLING HARD PROBLEMS We can work on the hardest targets including previously undrugged proteins, and we've delivered _in vivo_ success in blocking protein-protein interactions and targets in the central nervoussystem.
ACADEMIC AWARDS PROGRAM Atomwise’s Artificial Intelligence Molecular Screen (AIMS) Awards program offers academic researchers virtual screening and compounds to pursue or further their drug discovery efforts. Please contact us at academics@atomwise.com to apply.Learn More
ATOMWISE & CHARLES RIVER FORM STRATEGIC ALLIANCE Atomwise and Charles River Laboratories form a strategic alliance to provide premier AI-powered drug discovery capabilities. Charles River’s clients gain access to Atomwise’s AI technology to improve novelty, quality and efficiency of preclinical drug discovery. The total potential value with success in all projects could exceed US$2.4billion.
VIEW PRESS RELEASE
Our team of medicinal chemists, structural biologists, and machine learning experts are world class.Meet The Team
_Left: An untreated EAE mouse. Right: An EAE mouse treated with an Atomwise-predicted small molecule therapy._ COMPUTING NEW TREATMENT FOR MULTIPLE SCLEROSIS We were able to inhibit a protein-protein interaction in the central nervous system for a multiple sclerosis project, with a molecule that is orally active in mouse models at 3 nM/g. WORKING TO FIGHT AN EPIDEMIC Ebola virus’ high lethality has left thousands orphaned since 1976. From a field of thousands of approved medicines, Atomwise discovered a drug candidate with no previous antiviral application that blocked Ebola infectivity across virus strains from multiple epidemics.EBOLA CASE STUDY
POWERED BY ATOMNET TECHNOLOGY AtomNet is the first deep learning neural network for structure based drug design and discovery. Its speed and accuracy make it the most advanced technology for small molecule binding affinity prediction.Our Technology
_Visualization of AtomNet searching for small molecules to bind to the human ROCK2 kinase._* Partners
* Corporate & Academic Partnerships* AIMS Awards
* CADDS
* Team
* News
* Contact
* Careers
Details
Copyright © 2024 ArchiveBay.com. All rights reserved. Terms of Use | Privacy Policy | DMCA | 2021 | Feedback | Advertising | RSS 2.0